EPS for CytoDyn Inc. (CYDY) Expected At $-0.06 as of July, 19

June 29, 2018 - By Daniel Cummings

CytoDyn Inc. (OTCMKTS:CYDY) Corporate Logo

CytoDyn Inc. (OTCMKTS:CYDY)’s earnings report is awaited on July, 19., RTT reports. CYDY is reaching $0.46 during the last trading session, after decreased 2.70%.CytoDyn Inc. has volume of 87,945 shares. Since June 29, 2017 CYDY has 0.00% and is . CYDY underperformed by 12.57% the S&P 500.

CytoDyn Inc., a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus infection.The firm is worth $100.60 million. The Company’s lead product under development for HIV infection include PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease.Currently it has negative earnings.

CytoDyn Inc. (OTCMKTS:CYDY) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.